Sun Pharmaceutical Industries has acquired a 100% stake in Sun Pharma Global Treasury Centre IFSC Limited for ₹9.50 crore. The entity, incorporated on September 8, 2026, will serve as the group’s global treasury centre.

Acquisition details

The acquisition involves the subscription to the initial equity share capital of the newly incorporated subsidiary through Sun Pharma Laboratories Limited. The transaction was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Role and regulatory framework

Based within the International Financial Services Centre (IFSC) at GIFT City, Gandhinagar, the unit is designated to operate as the global treasury centre for the Sun Pharma Group. Its functions include centralising treasury, funding, liquidity, and cash management activities.

The company stated that registration and approval from the International Financial Services Centres Authority will be obtained to undertake these proposed activities. As a newly incorporated entity, it has not commenced operations and has no turnover.

Sun Pharmaceutical Industries secured two-year US tariff relief through a deal involving Most Favored Nation (MFN) drug pricing. The company also acquired Organon for $11.75 billion to expand its US market presence.

Key developments at a glance

The combined announcements highlight Sun Pharma's strategic alignment with US trade and pricing policies while executing major inorganic growth. The table below summarises the key updates:

Tariff relief linked to MFN pricing

Sun Pharma's support for the White House's medicine access initiative, which adopts MFN pricing for US Medicaid, has resulted in a two-year deferral of Section 232 tariffs. This specific timeframe clarifies the duration of the trade policy relief previously noted as a general deferral.

Organon acquisition for $11.75 billion

Sun Pharma's acquisition of Organon for $11.75 billion remains a central pillar of its US strategy. The deal is positioned to significantly boost the company's portfolio and scale in one of the world's largest pharmaceutical markets.